Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis
A live, multi-source view of Ionis Pharmaceuticals, Inc. (IONS): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease.
Sector: Healthcare · Industry: Biotechnology · United States · 1,480 employees · ionis.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Ionis Pharmaceuticals, Inc. (IONS) had a market capitalization of $9.65B (forward -53.6) and a beta of 0.42; the shares traded in a 52-week range of $50.01 – $86.74 (-4.8% over the year).
- Market cap
- $9.65B
- Enterprise value
- $9.74B
- Forward P/E
- -53.6
- PEG ratio
- 27.33
- Price / book
- 21.88
- EPS (trailing)
- $-3.48
- EPS (forward)
- $-1.08
- Payout ratio
- 0.0%
- 52-week range
- $50.01 – $86.74
- 52-week change
- -4.8%
- Beta
- 0.42
- Average volume
- 3.0M
- Shares outstanding
- 166.2M
- Short % of float
- 16.66%
- Profit margin
- -64.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Ionis Pharmaceuticals, Inc. (IONS) last closed at $55.65 (the last completed close before that scan).
Technicals at the scan: RSI 39 (neutral territory), price -6.4% versus its 20-day average, 20-day versus 50-day average spread -0.5%, MACD histogram -0.48.
Sentiment inputs: 50% of recent Finnhub-scored headlines read bullish; StockTwits 86% bullish; analyst consensus score 79/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of IONS; corporate insiders filed 2 buys and 0 sells (1 filer, latest disclosure 2026-07-31). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Michael R. Hayden (2B/0S). Who is trading what
RapidTradeView pick record
IONS has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Ionis Pharmaceuticals, Inc. (IONS) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell IONS.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.